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http://dx.doi.org/10.1016/j.jmii.2015
1684-1182/Copyright ª 2015, TaiwanAbstract Background/Purpose: Acute leukemia is the most common pediatric hematological
malignancy. Bloodstream infections (BSIs) are severe complications in these patients during
chemotherapy. This study aims to explore clinical features, laboratory, and microbiological
characteristics of BSIs in acute leukemic children.
Methods: Patients aged < 18 years, diagnosed with acute myeloid leukemia or acute lympho-
cytic leukemia with BSIs from January 2004 to December 2013 were enrolled. BSIs was defined
as positive isolate(s) of blood culture and associated with clinical findings. Clinical presenta-
tions, demographic features, and microbiological findings were retrospectively reviewed.
Results: In total, 126 isolates of 115 episodes of BSIs were identified from 69 patients (acute
lymphocytic leukemia 56; acute myeloid leukemia 13). Gram-negative bacteria (GNB), gram-
positive cocci, and fungi constituted 56.3%, 42.3%, and 2.4% of the pathogens, respectively.
Eighty-three and a half percent of BSIs occurred along with neutropenia, and 73% had severe
neutropenia. GNB was the leading pathogen of BSIs. The major GNBs were Escherichia coli,
Klebsiella pneumonia, and Pseudomonas aeruginosa.White blood cell counts, absolute neutro-
phil counts, and platelet counts were significantly lower in patients of BSIs caused by GNB than
gram-positive cocci. Plasma level of C-reactive protein was significant high in patients of GNB
BSIs (179.8 mg/L vs. 127.2 mg/L; pZ 0.005). Eighty-two percent of patients of E. coli, K. pneu-
monia, and P. aeruginosa BSIs had sepsis related organ failure or organ dysfunction. P.t of Pediatrics, National Cheng Kung University Hospital, Number 138, Sheng-Li Road, Tainan
du.tw (C.-C. Liu).
o F-C, et al., Bloodstream infections in pediatric patients with acute leukemia: Emphasis on gram-
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negative bacteria infections, Journaaeruginosa BSIs had the highest case-mortality (40%).
Conclusion: Neutropenia was the major risk factor of BSIs in pediatric leukemic patients. BSIs
of GNB were associated with severe neutropenia, systemic inflammatory responses, and high
mortality.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Acute leukemia is the most common hematological malig-
nancy in children, representing about 35% of all childhood
cancers.1 Advances in antimicrobial prophylaxis and
chemotherapy have decreased the disease severity and
improved the survival rate. Infectious complications are
still the major causes of morbidity and mortality in hema-
tological and oncological patients. Certain malignancies are
inherently associated with immune deficits.2 For example,
patients with lymphocytic leukemia frequently have hypo-
gammaglobulinemia leading to increased susceptibility to
encapsulated bacteria. Such patients may have recurrent
pulmonary infections and bacteremia. Patients with Hodg-
kin disease are at risk for opportunistic infections due to T-
cell abnormalities.3 However, most opportunistic infections
occur during treatment with cytotoxic and immunosup-
pressive therapy.
Elevated quality of supportive care has permitted pa-
tients to recover successfully from the side effects of
cytotoxic chemotherapy, radiation therapy, and intense
immunosuppression agents. Nonetheless, the increasing use
of novel aggressive chemotherapies and immunosuppres-
sant agents, including biological response-modifying
agents, has led to a growing population of patients with
deficits in humoral- and cell-mediated immunity. Bacteria
represent the immediate threat to most immunocompro-
mised hosts. Bloodstream infections (BSIs) are still the
cardinal infections through the course of chemotherapy in
leukemic patients and may lead to fatality, even if anti-
bacterial/antifungal prophylactic regimens have been
administered.
To improve the care quality and survival of leukemia
patients with BSIs, it is important to understand the risk
factors for BSI during the course of chemotherapy for high-
risk patients. The aims of this study were to explore the
clinical manifestations, laboratory data, systemic compli-
cations, and microbiological characteristics of BSIs in pe-
diatric leukemic patients.
Methods
Patients and setting
Patients aged < 18 years, diagnosed with acute leukemia at
the Department of Pediatrics, National Cheng Kung Uni-
versity Hospital, Tainan, Taiwan, from January 2004 to
December 2013 were enrolled. The Institutional Review
Board of National Cheng Kung University Hospital approved
this study (/A-ER-103-406).o F-C, et al., Bloodstream infect
l of Microbiology, Immunology andDefinitions and laboratory analysis
Blood cultures were obtained routinely from acute
leukemic patients with fever ( 38C) or hypothermia (
35C), and in association with nonspecific signs and other
organ or systemic symptoms. Respiratory symptoms (cough,
rhinorrhea, and respiratory distress), gastrointestinal
symptoms (nausea, vomiting, diarrhea, and abdominal
pain), consciousness disturbance, mucositis, and rash were
monitored. Other cutaneous signs of inflammation such as
local heat, swelling, exudate, fluctuation, and ulceration
were often diminished in neutropenic leukemia patients
due to an impaired inflammatory response. At least one set
of blood culture was obtained whenever infection was
suspected, before empirical antibiotic treatment. All
eligible patients were hospitalized when they met the
criteria of the above-mentioned conditions. The following
laboratory tests were performed: complete blood cell
count, differential count of white blood cells (WBC), C-
reactive protein (CRP), liver and renal function tests, chest
X-ray, urinalysis, and urine and blood cultures.
BSI was defined as a patient having identified patho-
gen(s) from one or more blood cultures. All blood cultures
were processed by the clinical microbiology laboratory
using the Bactec 9240 system (Becton, Dickinson and
Company, Franklin Lakes, NJ, USA). Coagulase-negative
staphylococci (CoNs) BSIs was defined as the same patho-
gens with the same antibiograms from at least two identi-
fied positive blood cultures. The definition of neutropenia is
according to the number of patients’ absolute neutrophil
count (ANC). Neutropenia was defined as ANC < 1500/mL.
Mild neutropenia was ANC from 1000e1500/mL, moderate
neutropenia was ANC from 500/mL to 1000/mL, and severe
neutropenia was ANC < 500/mL.Antimicrobial susceptibility test
Antimicrobial susceptibility test was determined using the
disk diffusion technique. The zone diameters of each drug
with the disk diffusion susceptibility method were inter-
preted using the criteria of the Clinical and Laboratory
Standards Institute (CLSI), and categorical assignment was
carried out by using CLSI breakpoints.4 The following agents
were tested: ertapenem, imipenem,meropenem, cefepime,
ceftazidime, cefotaxime, piperacillin/tazobactam, ampi-
cillin/sulbactam, ciprofloxacin, levofloxacin, gentamicin,
amikacin, and flomoxef. Extended-spectrum b-lactamases
(ESBL) production was screened and confirmed in all isolates
by performing a double-disc synergy test of CLSI guidelines.4
Among the P. aeruginosa isolates, extensively-drug resistantions in pediatric patients with acute leukemia: Emphasis on gram-
Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.08.013
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agents in all but in two or more categories of antimicrobial
agents, multidrug-resistant (MDR) P. aeruginosa was defined
as nonsusceptible to one or more agents in three or more
antimicrobial categories all antimicrobial agents, and pan
drug-resistant P. aeruginosa was defined as nonsusceptible
to all antimicrobial agents. The antimicrobial categories
were including aminoglycosides, antipseudomonal carbape-
nems, antipseudomonal cephalosporins, antipseudomonal
fluoroquinolones, antipseudomonal penicillins plus b-lacta-
mase inhibitors, phosphonic acids, and polymyxins.5
Therapeutic regimens of antibiotics treatment
Antibacterials were initiated at the onset of fever as fol-
lowings: in neutropenic patients, piperacillin/tazobactum
plus amikacin (from June 2012 to December 2013) or
cefazolin plus piperacillin plus gentamicin (from June 2004
to December 2012). In non-neutropenic patients, ampi-
cillin/sulbactam or cefazolin plus gentamicin were admin-
istrated. If patients still had persistent fever after initiation
of antibiotics for 3 days, or once fever subsided but infec-
tious signs recurred subsequently under the same thera-
peutic regimens, the laboratory tests were reexamined and
the original antimicrobial regimens were reevaluated.
Statistical analysis
The significance of differences in proportions data was
determined using nonparametric statistics of two-tailed c2
test and Kruskal-Wallis H test. A p value < 0.05 was consid-
ered to be statistically significant. All the data were per-
formed using SPSS version 17 (SPSS Inc., Chicago, IL, USA).
Results
Demography data
Overall, 186 patients were diagnosis with acute leukemia,
including 157 patients with acute lymphoblastic leukemia
(ALL) and 29 with acute myeloid leukemia (AML). There
were 115 episodes of BSIs that occurred in these patients
and 126 isolates were identified. There were 93 episodes of
BSIs in ALL patients, and 22 episodes of BSIs in AML pa-
tients. The men-to-women ratio was 1.67 (72:43), and the
mean age was 9.2  6.3 years. In ALL patients, the 1e5
years old group were the dominate age group (41.2%), but
in AML patients the age distribution was average.
Clinical symptoms/signs and systemic complications
Only 2.6% of patients had underlying disease. The under-
lying diseases included congenital heart disease, mental
retardation, Down syndrome, and chronic inflammatory
demyelinating polyneuropathy. The most common clinical
symptom was fever (95.7%) followed by respiratory symp-
toms (9.6%), mucosa damage (6.1%), gastrointestinal
symptoms (6.1%), consciousness disturbance (1.7%), and
rash (1.7%). Thirty-five cases (30.4%) had systemic compli-
cations (sepsis related organ failure or organ dysfunction),Please cite this article in press as: Kuo F-C, et al., Bloodstream infect
negative bacteria infections, Journal of Microbiology, Immunology andincluding shock/hypotension (24.3%), septic emboli (10%),
acute renal function (5.6%), liver function impairment
(4.3%), or central nervous system involvements (4.2%). The
overall case fatality rate was 10.4% (12/115).
Laboratory and microbiological findings
Ninety-six (83.5%) episodes of BSIs occurred in association
with neutropenia, and 73% patients had severe neu-
tropenia. Laboratory data showed that the CRP level is
significant higher in AML than ALL patients (191.9 mg/L vs.
146.8 mg/L; pZ 0.042). WBC was significantly lower in ALL
patients than AML (2300/mm3 vs. 4400/mm3; p Z 0.013).
Demographic data, clinical symptoms/signs, complications,
and mortality did not show significant difference between
ALL and AML patients.
Among gram-positive organisms of BSIs, CoNS (23.8%),
Streptococcus spp. (7.1%), Enterococcus spp. (2.4%), and
oxacillin-resistant Staphylococcus aureus (3.2%) were the
major pathogens. As for the gram-negative organisms,
Escherichia coli (22.2%), Klebsiella pneumoniae (13.5%),
Pseudomonas aeruginosa (7.9%), and Enterobacter spp.
(4%) dominated. Three episodes of fungal infections were
noted, including Candida albicans, Candida tropicalis, and
Cryptococcus neoformans, respectively (Table 1). There
was no difference in the percentage of causative patho-
gens, gram-positive cocci and gram-negative bacteria
(GNB), between AML and ALL patients.
In comparison with BSIs of gram-positive cocci, sixty-five
(91.5%) GNB BSIs occurred in association with severe neu-
tropenia. Patients with GNB BSIs had significantly lower
WBC (3300/mL vs. 12,900/mL; p Z 0.001), ANC (606/mL vs.
1256/mL; p Z 0.041), and platelet counts (65  103/mL vs.
120  103/mL; pZ 0.039); and significantly higher CRP level
(179.3 mg/L vs. 127.2 mg/L; pZ 0.005). Patients with GNB
BSIs had more systemic complications of shock/hypoten-
sion. (32.4% vs. 9.6%; p Z 0.001; Table 2).
In patients with GNB BSIs, the mean WBC were 1700/mL,
600/mL, and 700/mL in E. coli, K. pneumoniae, and P. aer-
uginosa BSIs patients, respectively. In comparison with
patients of E. coli BSI, significantly lower WBC (700/mL vs.
1700/mL) and ANC (255/mL vs. 713/mL) were found in pa-
tients of P. aeruginosa BSIs (p < 0.05). The mean plasma
level of CRP showed 218.6 mg/L, 208.5 mg/L, and
135.3 mg/L, respectively. The level of direct form bilirubin
was significant higher in patients of P. aeruginosa BSIs than
in patients of E. coli and K. pneumoniae BSI (7.5 mg/dL vs.
3.8 mg/dL vs. 1.0 mg/dL; pZ 0.031). Among patients of E.
coli, K. pneumonia, and P. aeruginosa BSI, 82% had systemic
complications, including septic shock (75% vs. 52.9% vs.
70%), liver function impairment (53.5% vs. 29.4% vs. 50%),
disseminated intravascular coagulation (46.2% vs. 35.3% vs.
30%), and acute renal function impairment (14.3% vs. 17.6%
vs. 20%). The highest mortality rate was patients with P.
aeruginosa BSI (40%) as compared with patients of E. coli
and K. pneumoniae BSI (14.3% and 11.8%; Table 3).
Antibiotics susceptibility test
Thirty-two percent (9/28) of the E. coli isolates were resis-
tant to cephalosporins, including 32.1% isolates (9/28)ions in pediatric patients with acute leukemia: Emphasis on gram-
Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.08.013
Table 1 Microbiological characteristics of bloodstream infections in acute leukemia children.
ALL
n Z 103
AML
n Z 23
Total
n Z 126
p
Gram positive bacteria 42/103 (40.8) 10/23 (43.5) 52/126 (42.3) 0.879
CoNS 23/103 (22.3) 7/23 (30.4) 30/126 (23.8) 0.706
Streptococcus spp. 7/103 (6.8) 2/23 (8.7) 9/126 (7.1) 0.762
Enterococcus 2/103 (1.9) 1/23 (4.3) 3/126 (2.4) 0.507
ORSA 4/103 (3.9) 0/23 (0) 4/126 (3.2) 0.782
Others 6/103 (0.9) 0/23 (0) 6/126 (4.8) 0.547
Gram negative bacteria 59/103 (57.3) 12/23 (52.2) 71/126 (56.3) 0.965
E. coli 24/103 (23.3) 4/23 (17.4) 28/126 (22.2) 0.822
K. pneumoniae 13/103 (12.6) 4/23 (17.4) 17/126 (13.5) 0.848
P. aeruginosa 8/103 (7.8) 2/23 (8.7) 10/126 (7.9) 0.891
Enterobacter spp. 5/103 (4.9) 0/23 (0) 5/126 (4) 0.650
Others 9/103 (8.7) 2/23 (8.7) 11/126 (8.7) 0.892
Fungia 2/103 (1.9) 1/23 (4.3) 3/126 (2.4) 0.507
a In ALL: one was Cryptococcus neoformans, another was Candida albican. In AML: Candida tropicalis.
Data are presented as n/N (%).
ALL Z acute lymphocytic leukemia; AML Z acute myeloid leukemia; CoNS Z coagulase-negative staphylococci; ORSA Z oxacillin-
resistant Staphylococcus aureus; E. coli Z Escherichia coli; K. pneumoniae Z Klebsiella pneumoniae; P. aeruginosa Z Pseudomonas
aeruginosa.
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(8/28) resistant to second generation cephalosporin (cefur-
oxime), 25% (7/28) resistant to third generation cephalo-
sporin (cefotaxime/ceftriaxone), six of 28 (21.4%) resistant
to fourth generation cephalosporin (cefepime), and 25% (7/
28) with ESBLs. Moreover, 35% (6/17) of the K. pneumoniae
isolates were resistant to cephalosporins, 17.6% (3/17) car-
ried with ESBLs. All the E. coli and K. pneumoniae isolates
were susceptible to carbapenems. Among P. aeruginosa
isolates, one isolate was extensively drug-resistant (10%),
one isolate was MDR (10%) but there was no pan drug-Table 2 Laboratory data, systemic complications, and mortali
negative bacteria in acute leukemia children.
BSIs
GPC
n Z 52
Laboratory data
WBC  103 (/mL) 12.9  55.4
ANC (/mL) 1256  2135
Neutropenic status 41 (78.8)
ANC < 500 (/mL) 32 (61.5)
500 < ANC < 1000 (/mL) 4 (7.7)
1000 < ANC < 1500 (/mL) 5 (9.6)
Peak CRP (mg/L) 127.2  138.7
Hb (g/dL) 10.7  3.5
PLT  103 (/mL) 120  142
Sepsis related organ failure/organ dysfunction
Shock/hypotension 5 (9.6)
Septic embolism 3 (5.8)
Meningitis 1 (1.9)
Mortality 4 (7.8)
Data are presented as n (%) or mean  standard deviation.
ANCZ absolute neutrophil counts; BSIsZ bloodstream infections; CR
negative bacteria; Hb Z hemoglobin; PLT Z platelet counts; WBC Z
Please cite this article in press as: Kuo F-C, et al., Bloodstream infect
negative bacteria infections, Journal of Microbiology, Immunology andresistant isolate. All P. aeruginosa isolates were suscepti-
ble to carbapenems and fluoroquinolones (Table 4).Discussion
In pediatric acute leukemia patients, BSIs are the one of the
most important infection complications and could lead to
high mortality during the course of treatment. Approxi-
mately 3250 new cases of leukemia are diagnosed annually
in the United States. ALL accounts for w80% of cases andty among bloodstream infections of gram positive and gram
Total
n Z 123
p
GNB
n Z 71
3.3  10.8 7.5  35.8 0.001
606  2037 911  2256 0.041
65 (91.5) 106 (86.2) 0.038
63 (88.7) 85 (69.1) 0.002
2 (2.8) 6 (4.9) 0.402
0 (0) 5 (4.1) 0.015
179.3  132.4 152.4  135.3 0.005
12.1  2.3 11.1  2.9 0.457
65  71 95  116 0.039
23 (32.4) 28 (22.8) 0.001
10 (14.1) 13 (10.6) 0.120
2 (2.8) 3 (2.4) 0.653
8 (11.1) 12 (9.8) 0.449
PZ C-reactive protein; GPCZ gram-positive cocci; GNBZ Gram-
white blood cell counts.
ions in pediatric patients with acute leukemia: Emphasis on gram-
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Table 3 Laboratory data, systemic complications, and mortality among bloodstream infections of Escherichia coli, Klebsiella
pneumonia, and Pseudomonas aeruginosa in acute leukemia children.
E. coli
n Z 28
K. pneumoniae
n Z 17
P. aeruginosa
n Z 10
Total
n Z 55
p
WBC  103 (/mL) 1.7  3.2 0.6  1.2 0.7  0.9 1.2  2.5 0.478
ANC (/mL) 713.2  2518 343.2  1283.9 255  616 525.6  1972.9 0.089
Hb (g/dL) 9.6  1.5 9.4  1.3 9.2  2.5 9.5  1.7 0.79
PLT  103 (/mL) 75.5  87.3 41.9  38.2 48.6  50.8 61.5  71.7 0.494
ESR (mm/h) 101.2  31.3 115.3  35.5 98.5  30.1 102.2  32.6 0.518
Dimer (ng/mL) 1192.5  1119.6 1770.1  1248.1 958.3  158.8 1301.8  1067.7 0.405
Peak CRP (mg/L) 218.6  150.6 208.5  106.2 135.4  94.2 200.7  132.6 0.312
AST (U/L) 98.8  91.3 47  41.7 72.4  53.9 80.5  77.3 0.109
ALT (U/L) 125.4  111.5 86.9  114.8 120.2  165 114.5  122.2 0.301
BUN (mg/dL) 15.4  10.2 15.9  7.9 15.5  7.8 15.6  9.1 0.734
Cr (mg/dL) 0.9  1.9 1.1  2.6 0.6  0.4 0.9  1.9 0.002
T-bil (mg/dL) 5.1  5.7 2.7  4.2 9.1  6.7 4.8  5.5 0.135
D-bil (mg/dL) 3.2  4.9 1  1.9 7.5  6.2 3  4.6 0.031
Neutropenic status 25/28 (89.3) 16/17 (94.1) 9/10 (90) 50/55 (90.9) 0.683
ANC <500 (/mL) 24/28 (85.7) 16/17 (94.1) 8/10 (80) 48/55 (87.3) 0.540
500 < ANC < 1000 (/mL) 1/28 (3.6) 0/17 (0) 0/10 (0) 1/55 (1.8) 0.617
1000 < ANC < 1500 (/mL) 0/28 (0) 0/17 (0) 1/10 (10) 1/55 (1.8) 0.105
Sepsis related organ failure/organ dysfunction
Shock/hypotension 21/28 (75) 9/17 (52.9) 7/10 (70) 37/55 (67.3) 0.311
Liver function impairment 15/28 (53.5) 5/17 (29.4) 5/10 (50) 25/55 (45.5) 0.355
DIC 13/28 (46.2) 6/17 (35.3) 3/10 (30) 19/55 (34.5) 0.683
AKI 4/28 (14.3) 3/17 (17.6) 2/10 (20) 9/55 (16.4) 0.925
Septic embolisma 5/28 (17.9) 2/17 (11.8) 1/10 (10) 8/55 (14.5) 0.251
Mortality 4/28 (14.3) 2/17 (11.8) 4/10 (40) 10/55 (18.2) 0.143
a Septic embolism including soft tissue necrotizing fasciitis and perianal abscess.
Data are presented as n/N (%) or mean  standard deviation.
AKI Z acute kidney injury; ALT Z and alanine transaminase; ANC Z absolute neutrophil counts; AST Z aspartate transaminase;
BUN Z blood urea nitrogen; Cr Z creatinine; CRPZ C-reactive protein; D-bil Z direct bilirubin; DIC Z disseminated intravascular
coagulation; E. coli Z Escherichia coli; ESR Z erythrocyte sedimentation rate; Hb Z hemoglobin; K. pneumoniae Z Klebsiella
pneumoniae; P. aeruginosaZ Pseudomonas aeruginosa; PLTZ platelet counts; T-bilZ total bilirubin; WBCZ white blood cell counts.
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of acute leukemia, AML patients received more cytotoxic
and intense chemotherapy than ALL patients.7 The
chemotherapy protocols of Taiwan Pediatric OncologyTable 4 Antibiotics susceptibility of Escherichia coli, Klebsie
bloodstream infections in pediatric acute leukemia patients.
E. co
n Z
1st generation cephalosporin resistance
(cefazolin)
9 (32
2nd generation cephalosporin resistance (cefuroxime) 8 (28
3rd generation cephalosporin resistance
(cefotaxime/ceftriaxone)
7 (25
4th generation cephalosporin resistance
(cefepime)
6 (21
Cephalosporinases (AmpCs) 9 (32
ESBLs 7 (25
Carbapenemase 0 (0)
Data are presented as n (%).
AmpCs Z AmpC b-lactamases; E. coli Z Escherichia coli; ESBLs Z
pneumoniae; NA Z not available; P. aeruginosa Z Pseudomonas aeru
Please cite this article in press as: Kuo F-C, et al., Bloodstream infect
negative bacteria infections, Journal of Microbiology, Immunology andGroup for AML included cytarabine, daunomycin, etopo-
side, idarubicin, and 6-thioguanine. The regimens caused
long duration of profound neutropenia and resulted in se-
vere mucositis to increase the susceptibility of infections.lla pneumonia, and Pseudomonas aeruginosa isolates from
li
28
K. pneumoniae
n Z 17
P. aeruginosa
n Z 10 (%)
Total
n Z 55
.1) 6 (35.9) 10 (100) 25 (45.5)
.6) 6 (35.9) 10 (100) 23 (41.8)
) 4 (23.5) 2 (20) 13 (23.6)
.4) 3 (17.6) 0 (0) 9 (16.4)
.1) 6 (35.9) 10 (100) 25 (45.5)
) 3 (17.6) NA 10 (18.2)
0 (0) 0 (0) 0 (0)
extended-spectrum b-lactamases; K. pneumoniae Z Klebsiella
ginosa.
ions in pediatric patients with acute leukemia: Emphasis on gram-
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+ MODELHost factors play a part in the clinical presentations,
laboratory data, and outcome of BSIs in ALL and AML pa-
tients. AML patients had a high rate of BSIs than ALL pa-
tients (79.3% vs. 61.8%). Furthermore, plasma level of CRP
was significant high in AML patients and WBC significantly
low in ALL patients. However, the other clinical symptoms/
signs, laboratory data, and systemic complications showed
no significant difference between groups.
Neutropenia was usually associated with life-threatening
opportunistic infections in the setting of cytotoxic chemo-
therapy. These episodes of febrile neutropenia might be
the result of BSIs with pathogenic micro-organisms. The
duration and degrees of the neutropenia underscored the
increased risk for life-threatening infections. Fever and
neutropenia in hematologic malignancies patients during
chemotherapy, and there were approximately 10e30% pa-
tients reported to be complicated with sepsis.8 However,
there have been limited data concerning morbidity and
mortality after developing sepsis in children and adoles-
cents with leukemia. In this study, 81.7% verified BSIs epi-
sodes occurred in association with neutropenia.
The spectrum of organisms responsible for infectious
complications in leukemic hosts is daunting, since virtually
any organism can become invasive if host defenses are
severely impaired. In the 1980s a rise in gram-positive in-
fections particularly due to CoNs led to a change in the
spectrum of pathogens. More recently the pendulum has
swung back with the re-emergence of gram-negative or-
ganisms producing ESBLs and carbapenemases. In this
study, GNB (55%) were the leading pathogens of BSIs.
Bacteremia due to GNB was a significant issue in both
hospitalized and community-dwelling patients.9 In a study,
45% of community-onset BSIs was due to GNB in contrast to
31% of hospital-onset infections.10 In the United States, the
National Nosocomial Infections Surveillance System re-
ported that the proportion of GNB BSIs in intensive care unit
(ICU) patients remained 25e30% from 1986 to 2003.11 The
leading pathogens of community acquired GNB BSIs were E.
coli, K. pneumoniae, and P. aeruginosa.12,13 Another study
also showed the distribution of community-onset GNB BSIs
was: E. coli (76%), P. aeruginosa (7.9%), and K. pneumoniae
(5.4%).14 BSIs of E. coli predominated in cases of
community-onset GNB. With hospital-onset GNB BSIs, the
distribution of pathogens were: E. coli (18%), K. pneumo-
niae (16%), and P. aeruginosa (8%).15 Another study of
hospital-onset bacteremia in ICUs, was led by P. aeruginosa
(22.2%), Enterobacter spp (22.2%), K. pneumoniae (17.8%),
E. coli (15.6%), and Serratia marcescens (11.1%).16 The
percentage of P. aeruginosa BSIs was frequently high among
ICU patients. Patients in ICU more frequent received anti-
biotics, which increased the risk of infections with P.
aeruginosa.
GNB sepsis with shock has a mortality rate of 12e38%;
mortality varies depending, in part, on whether the patient
received timely and appropriate antibiotic therapy.17e19
But those organisms had serious therapeutic problems
because of the increasing incidence of MDR.9 MDR bacteria
accounted for 44% of the identified bacteria in a previous
study.20 The burden of antimicrobial resistance among GNB
BSIs was substantial. Since the 1990s, the rise of MDR GNB
infections had posed a major clinical problem worldwide.
MDR GNB infections result in increased morbidity andPlease cite this article in press as: Kuo F-C, et al., Bloodstream infect
negative bacteria infections, Journal of Microbiology, Immunology andmortality and have now made their way to children.21 The
most common resistant GNB to antibiotics including three
important b-lactamases: cephalosporinases of AmpC b-
lactamases, ESBLs, and carbapenemases.22
MDR P. aeruginosa was found with high mortality than
susceptible P. aeruginosa in patients (36% vs. 27%).23
However, MDR P. aeruginosa was not a risk factor associ-
ated to mortality by multivariate analysis. Among those BSIs
of MDR P. aeruginosa, the mortality of used appropriate
antibiotics and with no antibiotic used was 83.3% and 18.8%
(p Z 0.011).24 In addition, another retrospective study of
BSIs of MDR GNB demonstrated that MDR GNB was not
associated with increased mortality.23 Whereas, it was
associated with the length of hospitalization but not the
susceptibility of pathogens.24 In our study, MDR GNB ac-
count for 45.5% isolates among E. coli, K. pneumonia, and
P. aeruginosa. However, these isolates were not associated
with significant high mortality. BSIs of MDR GNB led to high
morbidity and mortality may be associated with inappro-
priate initial antibiotic treatment.
This study had several limitations. Firstly, the clinical
presentations, physical examinations, and laboratory data
were obtained from medical records, so some incomplete
data was inevitable due to the retrospective design. Sec-
ondly, the case numbers were small, some characteristics
of clinical and laboratory items showed only marginal on
limited statistical significance.
In conclusion, BSIs of pediatric acute leukemic patients
remain severe infections and complications. The risk fac-
tors associated with BSIs were GNB pathogens and neu-
tropenic fever. However, the case-fatality rate was still
high under broad spectrum antimicrobial therapy. Early
identification of BSIs and implementation of empiric anti-
biotics is essential in managing leukemic patients with
neutropenic fever.Conflicts of interest
The authors declare no conflicts of interest.References
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